ReviewFrontiers in immunology2019
Early Identification of Chronic Lung Allograft Dysfunction: The Need of Biomarkers.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07234760 (ex Vivo Study of Liposomes Loaded With Everolimus in Chronic Lung Allograft Disfunction), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ex Vivo Study of Liposomes Loaded With Everolimus in Chronic Lung Allograft Disfunction
Who cites it
34 citing papers in PubMed, 77 citations in OpenAlex.
- Outcomes after lung retransplantation for restrictive allograft syndrome have not improved over 2 decades.JTCVS open · 2026Article
- BALF Lymphocyte and Cytokine Profiling as Biomarkers of Acute Rejection After Lung Transplantation.Journal of personalized medicine · 2025Article
- Proteomic Analysis of Transbronchial Biopsies to Discover Novel Biomarkers for Early Identification of Chronic Lung Allograft Dysfunction.Transplantation direct · 2025Article
- METTL3 Potentiates M2 Macrophage-Driven MMT to Aggravate Renal Allograft Fibrosis via the TGF-β1/Smad3 Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Donor-derived cell-free DNA for detection of acute rejection in lung transplant recipients.Frontiers in immunology · 2025Article
- Small airway brush gene expression predicts chronic lung allograft dysfunction and mortality.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2024Article
- Microbiome and metabolome patterns after lung transplantation reflect underlying disease and chronic lung allograft dysfunction.Microbiome · 2024Article
- HyperpolarizedJHLT open · 2024Article
- Pseudomonas aeruginosa infection correlates with high MFI donor-specific antibody development following lung transplantation with consequential graft loss and shortened CLAD-free survival.Respiratory research · 2024Article
- Macrophage and CD8 T cell discordance are associated with acute lung allograft dysfunction progression.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2024Article
- Article
- Donor Fractions of Cell-Free DNA Are Elevated During CLAD But Not During Infectious Complications After Lung Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Immune responses of lung transplant recipients against SARS-CoV-2 and common respiratory coronaviruses: Evidence for pre-existing cross-reactive immunity.Transplant immunology · 2023Article
- An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro.Pharmaceutics · 2023Article
- Application of plasma donor-derived cell free DNA for lung allograft rejection diagnosis in lung transplant recipients.BMC pulmonary medicine · 2023Article
- Systems prediction of chronic lung allograft dysfunction: Results and perspectives from the Cohort of Lung Transplantation and Systems prediction of Chronic Lung Allograft Dysfunction cohorts.Frontiers in medicine · 2023Review
- Assessment of dd-cfDNA Levels in Clinically Stable Lung Allograft Recipients Beyond the Initial 2 y Posttransplant.Transplantation direct · 2022Article
- Chronic Lung Allograft Dysfunction Is Associated with Increased Levels of Cell-Free Mitochondrial DNA in Bronchoalveolar Lavage Fluid of Lung Transplant Recipients.Journal of clinical medicine · 2022Article
- Corticotropin releasing hormone as an identifier of bronchiolitis obliterans syndrome.Scientific reports · 2022Article
- Cell-free DNA as a biomarker after lung transplantation: A proof-of-concept study.Immunity, inflammation and disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A growing number of patients with end-stage lung disease have benefited from lung transplantation (LT). Improvements in organ procurement, surgical techniques and intensive care management have greatly increased short-term graft survival. However, long-term outcomes remain limited, mainly due to the onset of chronic lung allograft dysfunction (CLAD), whose diagnosis is based on permanent loss of lung function after the development of irreversible lung lesions. CLAD is associated with high mortality and morbidity, and its exact physiopathology is still only partially understood. Many researchers and clinicians have searched for CLAD biomarkers to improve diagnosis, to refine the phenotypes associated with differential prognosis and to identify early biological processes that lead to CLAD to enable an early intervention that could modify the inevitable degradation of respiratory function. Donor-specific antibodies are currently the only biomarkers used in routine clinical practice, and their significance for accurately predicting CLAD is still debated. We describe here significant studies that have highlighted potential candidates for reliable and non-invasive biomarkers of CLAD in the fields of imaging and functional monitoring, humoral immunity, cell-mediated immunity, allograft injury, airway remodeling and gene expression. Such biomarkers would improve CLAD prediction and allow differential LT management regarding CLAD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.